CDC New Study Shows Pfizer, Moderna COVID-19 Shots 90% Effective Against Infection In Real-World Setting - Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX)

The two-dose COVID-19 vaccines from Pfizer Inc PFE - BioNTech SE BNTX and Moderna Inc MRNA lower the risk for infection by up to 90%, according to data released by the U.S. Centers for Disease Control and Prevention.
The study was released in Morbidity and Mortality Weekly Report, an online journal published by the Centers for Disease Control and Prevention.
The study followed 3,950 health care workers, first responders, and other essential workers in eight U.S. locations as the first vaccines were rolled out starting in December.
Participants were tested weekly to look for all cases of the infection, even asymptomatic ones.
According to the CDC, even two weeks after those studied received the first dose of a two-dose vaccine, the risk of infection dropped by 80%.
"The authorized COVID-19 vaccines provided early, substantial real-world protection against infection for our nation's healthcare personnel, first responders, and other front-line essential workers," CDC Director Dr. Rochelle P. Walensky said in a press release.
Price Action: PFE shares are trading 0.9% higher at $36.56, while BNTX and MRNA shares are down 1.44% at $94.38 and 7.15% at $123.75 in market trading hours on the last check Monday.